BioNxt Solutions Inc. (BNXTF)
OTCMKTS · Delayed Price · Currency is USD
0.7500
0.00 (0.00%)
Aug 22, 2025, 4:00 PM EDT
BioNxt Solutions Revenue
BioNxt Solutions had revenue of 22.85K CAD in the twelve months ending March 31, 2025, down -88.95% year-over-year. In the year 2024, BioNxt Solutions had annual revenue of 26.99K, down -92.75%.
Revenue (ttm)
22.85K CAD
Revenue Growth
-88.95%
P/S Ratio
5,460.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
86.81M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
Dec 31, 2020 | 345.65K | 137.54K | 66.08% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Elite Pharmaceuticals | 105.45M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
BioNxt Solutions News
- 20 days ago - BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement - Accesswire
- 23 days ago - BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment - Accesswire
- 4 weeks ago - BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement - Accesswire
- 5 weeks ago - BioNxt Delivers Positive Results in Patented Cladribine Sublingual Thin-Film Program and Completes Successful Formulation - Accesswire
- 6 weeks ago - BioNxt Solutions Announces Convertible Debenture Unit Private Placement - Accesswire
- 7 weeks ago - BioNxt Solutions Introduces Targeted Chemotherapy Drug Delivery Platform for Precision Oncology - Accesswire
- 7 weeks ago - BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase - Accesswire
- 2 months ago - BioNxt Solutions Announces Revocation of Management Cease Trade Order - Accesswire